Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2012

Open Access 01-12-2012 | Review

Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy

Authors: Julie Gutman, S Patrick Kachur, Laurence Slutsker, Alexis Nzila, Theonest Mutabingwa

Published in: Malaria Journal | Issue 1/2012

Login to get access

Abstract

The antifolate sulphadoxine-pyrimethamine (SP) has been used in the intermittent prevention of malaria in pregnancy (IPTp). SP is an ideal choice for IPTp, however, as resistance of Plasmodium falciparum to SP increases, data are accumulating that SP may no longer provide benefit in areas of high-level resistance. Probenecid was initially used as an adjunctive therapy to increase the blood concentration of penicillin; it has since been used to augment concentrations of other drugs, including antifolates. The addition of probenecid has been shown to increase the treatment efficacy of SP against malaria, suggesting that the combination of probenecid plus SP may prolong the useful lifespan of SP as an effective agent for IPTp. Here, the literature on the pharmacokinetics, adverse reactions, interactions and available data on the use of these drugs in pregnancy is reviewed, and the possible utility of an SP-probenecid combination is discussed. This article concludes by calling for further research into this potentially useful combination.
Appendix
Available only for authorised users
Literature
1.
ter Kuile FO, van Eijk AM, Filler SJ: Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. JAMA. 2007, 297: 2603-2616. 10.1001/jama.297.23.2603.CrossRefPubMed
2.
Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M: Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009, 374: 1533-1542. 10.1016/S0140-6736(09)61258-7.CrossRefPubMed
3.
Dicko A, Sagara I, Sissoko M, Guindo O, Diallo A, Kone M, Toure O, Sacko M, Doumbo O: Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J. 2008, 7: 123-10.1186/1475-2875-7-123.PubMedCentralCrossRefPubMed
4.
Thwing J, Eisele TP, Steketee RW: Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Publ Health. 2011, 11 (Suppl 3): S14-10.1186/1471-2458-11-S3-S14.CrossRef
5.
Wilson A, IPTc Taskforce: A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One. 2011, 6: e16976-10.1371/journal.pone.0016976.PubMedCentralCrossRefPubMed
6.
Greenwood B: Review: Intermittent preventive treatment--a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health. 2006, 11: 983-91. 10.1111/j.1365-3156.2006.01657.x.CrossRefPubMed
7.
Gosling RD, Carneiro I, Chandramohan D: Intermittent preventive treatment of malaria in infants: how does it work and where will it work?. Trop Med Int Health. 2009, 14: 1003-1010. 10.1111/j.1365-3156.2009.02303.x.CrossRefPubMed
8.
Maiga OM, Kayentao K, Traoré BT, Djimde A, Traoré B, Diallo M, Ongoiba A, Doumtabé D, Doumbo S, Traoré MS, Dara A, Guindo O, Karim DM, Coulibaly S, Bougoudogo F, Ter Kuile FO, Danis M, Doumbo OK: Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in Mali: a randomized controlled trial. Clin Infect Dis. 2011, 53: 215-223. 10.1093/cid/cir374.CrossRefPubMed
9.
World Health Organization: Susceptibility of Plasmodium falciparum to antimalarial drugs: Report on global monitoring: 1996-2004. Technical document WHO/HTM/MAL/20051103 Geneva: World Health Organization. 2005
10.
Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D: High resistance of Plasmodium falciparu to sulphadoxine/pyrimethamine in Northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS One. 2009, 4: e4569-10.1371/journal.pone.0004569.PubMedCentralCrossRefPubMed
11.
World Health Organization: Guidelines for the treatment of malaria. 2010, Geneva: WHO, 2
12.
Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE: Competitive facilitation of drug-resistant Plasmodium falciparu malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci USA. 2009, 106: 9027-9032. 10.1073/pnas.0901415106.PubMedCentralCrossRefPubMed
13.
Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE: Intermittent Treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011, 53: 224-230. 10.1093/cid/cir376.PubMedCentralCrossRefPubMed
14.
Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ: Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. PLoS One. 2010, 5: e12012-10.1371/journal.pone.0012012.PubMedCentralCrossRefPubMed
15.
Gosling RD, Cairns ME, Chico RM, Chandramohan D: Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther. 2010, 8: 589-606. 10.1586/eri.10.36.CrossRefPubMed
16.
Nzila AM, Kokwaro G, Winstanley PA, Marsh K, Ward SA: Therapeutic potential of folate uptake inhibition in Plasmodium falciparu. Trends Parasitol. 2004, 20: 109-112. 10.1016/j.pt.2003.12.005.CrossRefPubMed
17.
Nzila A, Mberu E, Bray P, Kokwaro G, Winstanley P, Marsh K, Ward S: Chemosensitization of Plasmodium falciparu by Probenecid In Vitro. Antimicrob Agents Chemother. 2003, 47: 2108-2112. 10.1128/AAC.47.7.2108-2112.2003.PubMedCentralCrossRefPubMed
18.
Sowunmi A, Adedeji AA, Fateye BA, Fehintola FA: Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparu gametocytes in children with acute, uncomplicated malaria. Ann Trop Med Parasitol. 2004, 98: 873-878. 10.1179/000349804X3243.CrossRefPubMed
19.
Sowunmi A, Fehintola FA, Adedeji AA, Gbotosho GO, Falade CO, Tambo E, Fateye BA, Happi TC, Oduola AMJ: Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop Med Int Health. 2004, 9: 606-614. 10.1111/j.1365-3156.2004.01233.x.CrossRefPubMed
20.
Mita T, Tanabe K, Kita K: Spread and evolution of Plasmodium falciparu drug resistance. Parasitol Int. 2009, 58: 201-209. 10.1016/j.parint.2009.04.004.CrossRefPubMed
21.
22.
Kublin J, Dzinjalamala F, Kamwendo D, Malkin E, Cortese J, Martino L, Mukadam R, Rogerson S, Lescano A, Molyneux M, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparu malaria. J Infect Dis. 2002, 185: 380-388. 10.1086/338566.CrossRefPubMed
23.
Gregson A, Plowe CV: Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev. 2005, 57: 117-145. 10.1124/pr.57.1.4.CrossRefPubMed
24.
Watkins WM, Mberu EK, Winstanley PA, Plowe CV: The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today. 1997, 13: 459-464. 10.1016/S0169-4758(97)01124-1.CrossRefPubMed
25.
Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, Little F, Cassam Y, Guirou E, Traore B, Doumbo O, Sullivan D, Smith P, Barnes KI: Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther. 2009, 87: 226-234.CrossRefPubMed
26.
Boger WP, Strickland SC: PROBENECID (BENEMID) Its Uses and Side-Effects in 2,502 Patients. AMA Arch Intern Med. 1955, 95: 83-92. 10.1001/archinte.1955.00250070099012.CrossRefPubMed
27.
Cunningham R, Israili ZH, Dayton PG: Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981, 6: 135-151. 10.2165/00003088-198106020-00004.CrossRefPubMed
28.
Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N: Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother. 2008, 52: 3013-3021. 10.1128/AAC.00047-08.PubMedCentralCrossRefPubMed
29.
Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN: Population pharmacokinetics of oseltamivir when coadministered with probenecid. J Clin Pharmacol. 2008, 48: 935-947. 10.1177/0091270008320317.CrossRefPubMed
30.
Wolf DL, Rodriguez CA, Mucci M, Ingrosso A, Duncan BA, Nickens DJ: Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol. 2003, 43: 43-51. 10.1177/0091270002239705.CrossRefPubMed
31.
32.
Roch-Ramel F: Renal transport of organic anions. Curr Opin Nephrol Hypertens. 1998, 7: 517-524. 10.1097/00041552-199809000-00006.CrossRefPubMed
33.
Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999, 274: 13675-13680. 10.1074/jbc.274.19.13675.CrossRefPubMed
34.
Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997, 272: 18526-18529. 10.1074/jbc.272.30.18526.CrossRefPubMed
35.
Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998, 438: 321-324. 10.1016/S0014-5793(98)01328-3.CrossRefPubMed
36.
Sirotnak FM, Wendel HG, Bornmann WGB, Tong WP, Miller VA, Scher HI, Kris MG: Co-administration of Probenecid, an inhibitor of a cMOAT/MRP- like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Clin Cancer Res. 2000, 6: 3705-3712.PubMed
37.
Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D: Resistance mechanisms to methotrexate in tumors. Oncologist. 1996, 1: 223-226.PubMed
38.
Watkins WM, Sixsmith DG, Chulay JD, Spencer HC: Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol Biochem Parasitol. 1985, 14: 55-61. 10.1016/0166-6851(85)90105-7.CrossRefPubMed
39.
Wang P, Sims PF, Hyde JE: A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparu suitable for investigating Fansidar resistance. Parasitology. 1997, 115 (Pt 3): 223-230.CrossRefPubMed
40.
Kinyanjui SM, Mberu EK, Winstanley PA, Jacobus DP, Watkins WM: The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitr activity against Plasmodium falciparu and a non- antifolate mode of action of the prodrug. AmJTrop Med Hyg. 1999, 60: 943-947.
41.
van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM: Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg. 1995, 89: 672-676. 10.1016/0035-9203(95)90438-7.CrossRefPubMed
42.
Kiara SM, Okombo J, Masseno V, Mwai L, Ochola I, Borrmann S, Nzila A: In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from Kenyan coast: Emergence of parasites with Ile-164-Leu mutation. Antimicrob Agents Chemother. 2009, 53: 3793-3798. 10.1128/AAC.00308-09.PubMedCentralCrossRefPubMed
43.
Sowunmi A, Adedeji AA, Fateye BA, Babalola CP: Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. Parasite. 2004, 11: 317-323.CrossRefPubMed
44.
Ilett KF, Hackett LP, Ingle B, Bretz PJ: Transfer of probenecid and cephalexin into breast milk. Ann Pharmacother. 2006, 40: 986-989. 10.1345/aph.1G580.CrossRefPubMed
45.
Anderson R, Gambertoglio JG, Schrier RW: Clinical use of drugs in renal failure. 1976, Springfield, Il: Charles C Thomas
46.
Weber A, de Groot R, Ramsey B, Williams-Warren J, Smith A: Probenecid pharmacokinetics in cystic fibrosis. Dev Pharmacol Ther. 1991, 16: 7-12.PubMed
47.
Selen A, Amidon GL, Welling PG: Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci. 1982, 71: 1238-1242. 10.1002/jps.2600711114.CrossRefPubMed
48.
Product Information: Benemid(R), probenecid tablets: Merck & Company. 1998, West Point, PA
49.
Bennett W, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DC: Drug prescribing in renal failure. 1987, Philadelphia: American College of Physicians
50.
51.
Peters PJ, Thigpen MC, Parise ME, Newman RD: Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 2007, 30: 481-501. 10.2165/00002018-200730060-00003.CrossRefPubMed
52.
53.
Green MD, van Eijk AM, van ter Kuile FO, Ayisi JG, Parise ME, Kager PA, Nahlen BL, Steketee R, Nettey H: Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Inf Dis. 2007, 196: 1403-1408. 10.1086/522632.CrossRef
54.
Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM: Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother. 2009, 53: 4368-4376. 10.1128/AAC.00335-09.PubMedCentralCrossRefPubMed
55.
Goodrich JT: Treatment of gonorrhea in pregnancy. Sex Transm Dis. 1979, 6 (2): 168-173. 10.1097/00007435-197904000-00023.CrossRefPubMed
56.
Swanson M, Cook R: Drugs, chemicals and blood dyscrasias. 1977, Hamilton, Il: Drug Intell Publications
57.
Marks PA, Banks J: Drug induced hemolytic anemias associated with glucose-6-phosphate dehydrogenase deficiency: a genetically heterogenous trait. Ann N Y Acad Sci. 1965, 123: 198-206.CrossRefPubMed
58.
59.
Zail S, Charlton RW, Bothwell TH: The hemolytic effect of certain drugs in Bantu subjects with a deficiency of glucose 6 phosphate dehydrogenase. S Afr Med J. 1972, 27: 95-99.
60.
Cappellini MD, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008, 371: 64-74. 10.1016/S0140-6736(08)60073-2.CrossRefPubMed
61.
Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M: Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 2010, 33: 713-726. 10.2165/11536520-000000000-00000.CrossRefPubMed
62.
Sosler S, Behzad O, Garratty G, Lee CL, Postoway N, Khomo O: Immune hemolytic anemia associated with probenecid. Am J Clin Pathol. 1985, 84: 391-394.PubMed
63.
Kickler T, Buck S, Ness P, Shirey RS, Sholar PW: Probenecid induced immune hemolytic anemia. J Rheumatol. 1986, 13: 208-209.PubMed
64.
Ferris TF, Morgan WS, Levitin H: Nephrotic syndrome caused by probenecid. NEJM. 1961, 265: 381-383. 10.1056/NEJM196108242650807.CrossRefPubMed
65.
Hertz P, Yager H, Richardson JA: Probenecid-induced nephritic syndrome. Arch Pathol. 1972, 94: 241-243.PubMed
66.
Izzedine H, Brocheriou I, Becart J, Deray G: Probenecid-induced membranous nephropathy. Nephrol Dial Transplant. 2007, 22: 2405-2406.CrossRefPubMed
67.
68.
Sokol A, Bashner MH, Okun R: Nephrotic syndrome caused by probenecid. JAMA. 1967, 199: 43-44. 10.1001/jama.1967.03120010087026.CrossRefPubMed
69.
Reynolds ES, Schlant RC, Gonick HC, Dammin GJ: Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid. NEJM. 1957, 256: 592-596. 10.1056/NEJM195703282561304.CrossRefPubMed
70.
Myers K, Katial RK, Engler RJ: Probenecid Hypersensitivity in AIDS: a Case Report. Ann Allergy Asthma Immunol. 1998, 80: 416-418. 10.1016/S1081-1206(10)62994-8.CrossRefPubMed
71.
Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, Jaffe HS: (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (Cidofovir): results of a phase i/ii study of a novel antiviral nucleotide analogue. J Inf Dis. 1995, 171: 788-796. 10.1093/infdis/171.4.788.CrossRef
72.
Petty B, Kornhauser D, Lietman P: Zidovudine with probenecid: a warning. Lancet. 1990, 335: 1044-1045.CrossRefPubMed
73.
Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT, Kovacs JA, Walker RE: Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995, 39: 882-886.PubMedCentralCrossRefPubMed
74.
Hillecke N: Acute anaphylactoid reaction to probenecid. JAMA. 1965, 193: 116-CrossRef
75.
Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW: Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg. 1998, 59: 813-822.PubMed
76.
Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel M: Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis. 2006, 194: 286-293. 10.1086/505080.CrossRefPubMed
77.
Hamer DH, Mwanakasale V, MacLeod WB, Chalwe V, Mukwamataba D, Champo D, Mwananyanda L, Chilengi R, Mubikayi L, Mulele CK, Mulenga M, Thea DM, Gill CJ: Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in hiv-seropositive pregnant Zambian Women. J Infect Dis. 2007, 196 (11): 1585-1594. 10.1086/522142.CrossRefPubMed
78.
Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC: Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (fansidar(r)) for malaria prophylaxis. Am J Trop Med Hyg. 1986, 35: 451-458.PubMed
79.
Hellgren U, Rombo L, Berg B, Carlson J, Wiholm BE: Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis. BMJ. 1987, 295: 365-366.PubMedCentralCrossRefPubMed
80.
Phillips-Howard P, West LJ: Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med. 1990, 83: 82-85.PubMedCentralPubMed
81.
Gimnig JE, MacArthur JR, M'Bang'Ombe M, Kramer MH, Chizani N, Stern RS, Mkandala C, Newman RD, Steketee RW, Campbell CH: Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg. 2006, 74: 738-743.PubMed
82.
Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P: Effect of Repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am J Trop Med Hyg. 2010, 83: 1212-1220. 10.4269/ajtmh.2010.10-0264.PubMedCentralCrossRefPubMed
83.
Khoo K: The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Ann Trop Med Parasitol. 1981, 75: 591-595.PubMed
84.
Cavenee MR, Farris JR, Spalding TR, Barnes DL, Castaneda YS, Wendel GD: Treatment of gonorrhea in pregnancy. Obstet Gynecol. 1993, 81: 33-38.PubMed
85.
Adelson M, Graves WL, Osborne NG: Treatment of urinary infections in pregnancy using single versus 10-day dosing. J Natl Med Assoc. 1992, 84: 73-75.PubMedCentralPubMed
86.
Brown C, Saffan BD, Howard CM, Preedy JR: The Renal clearance of endogenous estrogens in late pregnancy. J Clin Invest. 1964, 43: 295-303. 10.1172/JCI104914.PubMedCentralCrossRefPubMed
87.
Lee FI, Loeffler FE: Gout and pregnancy. J Obstet Gynaecol Br Emp. 1962, 69 (2): 299-304. 10.1111/j.1471-0528.1962.tb00046.x.CrossRefPubMed
88.
Weingold AB: Gout and Pregnancy. Obstet Gynecol. 1960, 16 (3): 309-313.PubMed
89.
Schackis RC: Hyperuricaemia and preeclampsia: is there a pathogenic link?. Med Hypotheses. 2004, 63: 239-244. 10.1016/j.mehy.2004.02.018.CrossRefPubMed
90.
Czaczkes W, Ullmann TD, Sadowsky E: Plasma uric acid levels, uric acid excretion, and response to probenecid in toxemia of pregnancy. J Lab Clin Med. 1958, 51: 224-229.PubMed
91.
Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA: Folic acid antagonists during pregnancy and the risk of birth defects. NEJM. 2000, 343: 1608-1614. 10.1056/NEJM200011303432204.CrossRefPubMed
92.
Sweet D: Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol Appl Pharmacol. 2005, 204: 198-215. 10.1016/j.taap.2004.10.016.CrossRefPubMed
93.
Anzai N, Kanai Y, Endou H: Organic anion transporter family: current knowledge. J Pharmacol Sci. 2006, 100: 411-426. 10.1254/jphs.CRJ06006X.CrossRefPubMed
94.
Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS: Clinical pharmacokinetics of cidofovir in human immunodeficiency virus- infected patients. Antimicrob Agents Chemother. 1995, 39: 1247-1252.PubMedCentralCrossRefPubMed
95.
Coleman M, Edwards G, Mihaly GW, Howells RE, Breckenridge AM: High-performance liquid chromatographic method for the determination of pyrimethamine and its 3-N-oxide metabolite in biological fluids. J Chromatogr. 1984, 308: 363-369.CrossRefPubMed
96.
Dua V, Gupta NC, Sethi P, Edwards G, Dash AP: High-performance liquid chromatographic assay for the determination of sulfadoxine and N-acetyl sulfadoxine in plasma from patients infected with sensitive and resistant Plasmodium falciparu malaria. J Chromatogr B Analyt Technol Biomed Life Sci. 2007, 860: 160-165. 10.1016/j.jchromb.2007.10.016.CrossRefPubMed
97.
World Health Organization: World Malaria Report 2009. 2009, Geneva: World Health OrganizationCrossRef
98.
World Health Organization. Malaria in Pregnancy Working Group: Minutes of the 8th Strategic Planning Meeting. 2007, Geneva: World Health Organization
Metadata
Title
Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy
Authors
Julie Gutman
S Patrick Kachur
Laurence Slutsker
Alexis Nzila
Theonest Mutabingwa
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2012
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-11-39

Other articles of this Issue 1/2012

Malaria Journal 1/2012 Go to the issue

Research

Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium

Research

Low antibodies against Plasmodium falciparum and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case–control study

Research

Anti-plasmodial action of de novo-designed, cationic, lysine-branched, amphipathic, helical peptides

Review

Human movement data for malaria control and elimination strategic planning

Research

Target product profiles for protecting against outdoor malaria transmission

Research

Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits